{"disease":{"id":"atrophy","name":"atrophy"},"drugs":{"marketed":[{"drug_id":"risdiplam","indication_name":"Spinal muscular atrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evrysdi","generic_name":"RISDIPLAM","company_name":"Roche","drug_phase":"marketed","molecular_target":"","drug_class":"Survival of Motor Neuron 2 Splicing Modifier [EPC]","quality_score":10,"revenue":"2300","mechanism":"Evrysdi works by increasing the production of survival motor neuron protein."},{"drug_id":"zolgensma","indication_name":"Spinal muscular atrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zolgensma","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":"925","mechanism":null},{"drug_id":"idebenone","indication_name":"Leber's optic atrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daruma","generic_name":"IDEBENONE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19","drug_class":"idebenone","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"estradiol","indication_name":"Urethral atrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"avacincaptad-pegol-sodium","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVACINCAPTAD PEGOL SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitors","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"menest","indication_name":"Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menest","generic_name":"Estrogens, Esterified","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Esterified estrogens, sold under the brand names Estratab and Menest, are used for hormone therapy and cancer treatment."},{"drug_id":"pf-06954522","indication_name":"Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 1, or SMA type 2 or 3 in patients with a body weight of 13 kg or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"nusinersen","indication_name":"Spinal muscular atrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spinraza","generic_name":"NUSINERSEN","company_name":"Biogen Idec","drug_phase":"marketed","molecular_target":"","drug_class":"Survival Motor Neuron-2-directed RNA Interaction [EPC]","quality_score":40,"revenue":null,"mechanism":"Spinraza works by binding to a specific genetic sequence to increase production of a protein that helps maintain muscle function."},{"drug_id":"estring","indication_name":"Urethral atrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"avacincaptad-pegol","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Izervay","generic_name":"AVACINCAPTAD PEGOL","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response."},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"onasemnogene-abeparvovec-brve","indication_name":"Spinal Muscular Atrophy (SMA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Onasemnogene Abeparvovec-brve","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"SMN1 gene","drug_class":"Gene Therapy","quality_score":10,"revenue":null,"mechanism":"ITVISMA delivers a functional SMN1 gene using an AAV9 vector to promote SMN protein expression in motor neurons."},{"drug_id":"avacincaptad","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avacincaptad","company_name":"Aviceda Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"avacincaptad-pegol","indication_name":"Geographic atrophy (GA) secondary to AMD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Izervay","generic_name":"AVACINCAPTAD PEGOL","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response."}],"pipeline":[],"offLabel":[],"totalMarketed":124,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05243823","title":"Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy","phase":"","overall_status":"COMPLETED","enrollment_count":500000,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06027385","title":"Genetic Newborn Screening for Cystinosis and Spinal Muscular Atrophy","phase":"NA","overall_status":"COMPLETED","enrollment_count":300000,"lead_sponsor_name":"Cystinose Stiftung","has_results":false},{"nct_id":"NCT03217578","title":"Neonatal Spinal Muscular Atrophy (SMA) Screening","phase":"","overall_status":"RECRUITING","enrollment_count":250000,"lead_sponsor_name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","has_results":false},{"nct_id":"NCT03554343","title":"Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium","phase":"","overall_status":"COMPLETED","enrollment_count":136339,"lead_sponsor_name":"Centre Hospitalier Régional de la Citadelle","has_results":false},{"nct_id":"NCT05891275","title":"Patients With Geographic Atrophy and Their Patient Journey in the United States (US)","phase":"","overall_status":"COMPLETED","enrollment_count":68563,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT05481164","title":"Newborn Screening for Spinal Muscular Atrophy","phase":"","overall_status":"COMPLETED","enrollment_count":33568,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT03047369","title":"The Myelin Disorders Biorepository Project","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT06310421","title":"Spinal Muscular Atrophy Neonatal Screening Program","phase":"","overall_status":"RECRUITING","enrollment_count":11500,"lead_sponsor_name":"IRCCS Burlo Garofolo","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT05775120","title":"Epidemiology of Helicobacter Pylori Infection in Moscow","phase":"","overall_status":"UNKNOWN","enrollment_count":5121,"lead_sponsor_name":"Moscow Clinical Scientific Center","has_results":false},{"nct_id":"NCT05237544","title":"Newborn Screening for Spinal Muscular Atrophy (SMA) - a Proof of Principle Study Using Anonymised Blood Spots.","phase":"","overall_status":"COMPLETED","enrollment_count":5065,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT05966038","title":"ALS/MND Natural History Study Data Repository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT07403214","title":"A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy","phase":"","overall_status":"COMPLETED","enrollment_count":4805,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07378943","title":"A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies","phase":"","overall_status":"COMPLETED","enrollment_count":4114,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06370143","title":"A Study Collecting Health Information to Understand and Prevent Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3200,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03924414","title":"Trial of Parkinson's And Zoledronic Acid","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2650,"lead_sponsor_name":"California Pacific Medical Center Research Institute","has_results":false},{"nct_id":"NCT05361148","title":"Long-term Health After Severe Acute Malnutrition in Children and Adults: the Role of the Pancreas","phase":"","overall_status":"COMPLETED","enrollment_count":2305,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT06949865","title":"AI-Enhanced Optimization of Acute Levodopa Challenge Test","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT04010604","title":"A Registered Cohort Study on SMA","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Wan-Jin Chen","has_results":false},{"nct_id":"NCT03555578","title":"Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg \"All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)\"","phase":"","overall_status":"RECRUITING","enrollment_count":1890,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05755451","title":"Natural History of SMA","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05698316","title":"A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Association for Innovation and Biomedical Research on Light and Image","has_results":false},{"nct_id":"NCT07222605","title":"Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"eQ8Health Corporation d/b/a CareONE Concierge","has_results":false},{"nct_id":"NCT04843397","title":"Diagnostic Performance Indicators in Upper GI Endoscopy:PROSPERO Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"University of Cambridge","has_results":false},{"nct_id":"NCT06779773","title":"A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT04177134","title":"French Register of Patients With Spinal Muscular Atrophy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05187260","title":"Antisense Oligonucleotide for Spinal Muscular Atrophy","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT04715399","title":"UPenn Observational Research Repository on Neurodegenerative Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06647641","title":"The CurePSP Genetics Program","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05890092","title":"Vulvar Disease in Nigeria Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"KDRS ltd","has_results":false},{"nct_id":"NCT03452956","title":"Cognitive Impairement In Frontotemporal Dementia","phase":"","overall_status":"COMPLETED","enrollment_count":997,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT02745119","title":"Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":994,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02247531","title":"A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":975,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06541704","title":"A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":975,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT02247479","title":"A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":906,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04607707","title":"Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":831,"lead_sponsor_name":"Shionogi","has_results":false},{"nct_id":"NCT04292574","title":"UK SMA Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT03660969","title":"Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal Muscle Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":797,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT04770545","title":"An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":792,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03076671","title":"More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":783,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04723160","title":"Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph","phase":"","overall_status":"COMPLETED","enrollment_count":748,"lead_sponsor_name":"Visionary Intelligence Ltd.","has_results":false},{"nct_id":"NCT01400776","title":"Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":722,"lead_sponsor_name":"Warner Chilcott","has_results":true},{"nct_id":"NCT07392411","title":"Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers","phase":"","overall_status":"RECRUITING","enrollment_count":720,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT01059240","title":"SMN Copy Number Distribution in Mali, West Africa","phase":"","overall_status":"COMPLETED","enrollment_count":701,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04174157","title":"Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07353463","title":"Shanghai Clinical Cohort - Parkinson's Disease (Reserve)","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06390579","title":"Building Research With Artificial Intelligence in Neuro-Ophthalmology","phase":"","overall_status":"COMPLETED","enrollment_count":693,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT06510816","title":"A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":659,"lead_sponsor_name":"Annexon, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}